Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Mast cells in innate and adaptive immunity to infection.

Palker TJ, Dong G, Leitner WW.

Eur J Immunol. 2010 Jan;40(1):13-8. doi: 10.1002/eji.200990325.

2.

Protection of beagle dogs from mucosal challenge with canine oral papillomavirus by immunization with recombinant adenoviruses expressing codon-optimized early genes.

Johnston KB, Monteiro JM, Schultz LD, Chen L, Wang F, Ausensi VA, Dell EC, Santos EB, Moore RA, Palker TJ, Stanley MA, Jansen KU.

Virology. 2005 Jun 5;336(2):208-18.

3.

Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles.

Palker TJ, Monteiro JM, Martin MM, Kakareka C, Smith JF, Cook JC, Joyce JG, Jansen KU.

Vaccine. 2001 Jun 14;19(27):3733-43.

PMID:
11395208
4.

Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.

Letvin NL, Robinson S, Rohne D, Axthelm MK, Fanton JW, Bilska M, Palker TJ, Liao HX, Haynes BF, Montefiori DC.

J Virol. 2001 May;75(9):4165-75.

5.

Developmental regulation of lymphocyte-specific protein 1 (LSP1) expression in thymus during human T-cell maturation.

Palker TJ, Fong AM, Scearce RM, Patel DD, Haynes BF.

Hybridoma. 1998 Dec;17(6):497-507.

PMID:
9890705
6.

Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative.

Bartlett JA, Wasserman SS, Hicks CB, Dodge RT, Weinhold KJ, Tacket CO, Ketter N, Wittek AE, Palker TJ, Haynes BF.

AIDS. 1998 Jul 30;12(11):1291-300.

PMID:
9708408
7.
9.

The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope.

Palker TJ, Muir AJ, Spragion DE, Staats HF, Langlois A, Montefiori DC.

Virology. 1996 Oct 15;224(2):415-26.

10.
11.

Characterization of an antigen shared by human thymic epithelium and human T cell leukemia virus p19 Gag protein.

Palker TJ, Singer KH, Vahlne A.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jan 1;11(1):10-9.

PMID:
8528727
12.

Effect of bismuth salts on systemic and mucosal immune responses to orally administered cholera toxin.

Horowitz NS, Staats HF, Palker TJ.

Immunopharmacology. 1995 Nov;31(1):31-41.

PMID:
8655289
13.

Design of experimental synthetic peptide immunogens for prevention of HIV-1 and HTLV-I retroviral infections.

Hart MK, Palker TJ, Haynes BF.

Pharm Biotechnol. 1995;6:821-45. Review. No abstract available.

PMID:
7551251
14.
15.

Synthetic peptide in mineral oil adjuvant elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes in rhesus monkeys.

Yasutomi Y, Palker TJ, Gardner MB, Haynes BF, Letvin NL.

J Immunol. 1993 Nov 1;151(9):5096-105.

PMID:
7691965
16.

Mother-to-child transmission of human T-cell lymphotropic virus type I (HTLV-I) in Jamaica: association with antibodies to envelope glycoprotein (gp46) epitopes.

Wiktor SZ, Pate EJ, Murphy EL, Palker TJ, Champegnie E, Ramlal A, Cranston B, Hanchard B, Blattner WA.

J Acquir Immune Defic Syndr. 1993 Oct;6(10):1162-7.

PMID:
7692038
17.

Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.

Haynes BF, Torres JV, Langlois AJ, Bolognesi DP, Gardner MB, Palker TJ, Scearce RM, Jones DM, Moody MA, McDanal C, et al.

J Immunol. 1993 Aug 1;151(3):1646-53.

PMID:
8335949
19.

Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein.

Haynes BF, Arthur LO, Frost P, Matthews TJ, Langlois AJ, Palker TJ, Hart MK, Scearce RM, Jones DM, McDanal C, et al.

J Exp Med. 1993 Mar 1;177(3):717-27.

20.

Expression and immunogenicity of the entire human T cell leukaemia virus type I envelope protein produced in a baculovirus system.

Arp J, Ford CM, Palker TJ, King EE, Dekaban GA.

J Gen Virol. 1993 Feb;74 ( Pt 2):211-22.

PMID:
8429302
22.

Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins.

Palker TJ, Riggs ER, Spragion DE, Muir AJ, Scearce RM, Randall RR, McAdams MW, McKnight A, Clapham PR, Weiss RA, et al.

J Virol. 1992 Oct;66(10):5879-89.

23.

Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides.

Hart MK, Weinhold KJ, Scearce RM, Washburn EM, Clark CA, Palker TJ, Haynes BF.

Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9448-52.

24.

A synthetic peptide elicits antibodies reactive with the external glycoprotein of human T cell lymphotropic virus type I.

Lal RB, Rudolph DL, Palker TJ, Coligan JE, Folks TM.

J Gen Virol. 1991 Sep;72 ( Pt 9):2321-4.

PMID:
1716657
26.

Early antibody profile during HTLV-I seroconversion.

Manns A, Murphy EL, Wilks RJ, Haynes G, Figueroa JP, Hanchard B, Palker TJ, Blattner WA.

Lancet. 1991 Jan 19;337(8734):181-2. No abstract available.

PMID:
1670825
27.
28.

SIV vaccine protection of rhesus monkeys.

Gardner MB, Carlson JR, Jennings M, Rosenthal A, Langlois A, Haynes B, Bolognesi D, Palker TJ.

Biotechnol Ther. 1991;2(1-2):9-19.

PMID:
1845125
29.

New AIDS vaccine candidates: antigen delivery and design.

Aldovini A, Young RA, Palker TJ.

AIDS. 1991;5 Suppl 2:S151-8. Review. No abstract available.

PMID:
1845045
30.

Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies.

Tyler DS, Stanley SD, Zolla-Pazner S, Gorny MK, Shadduck PP, Langlois AJ, Matthews TJ, Bolognesi DP, Palker TJ, Weinhold KJ.

J Immunol. 1990 Nov 15;145(10):3276-82.

PMID:
1700004
31.

Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys.

Hart MK, Palker TJ, Matthews TJ, Langlois AJ, Lerche NW, Martin ME, Scearce RM, McDanal C, Bolognesi DP, Haynes BF.

J Immunol. 1990 Oct 15;145(8):2677-85.

PMID:
1698859
32.

Characterization of the surface topography and putative tertiary structure of the human CD7 molecule.

Ware RE, Scearce RM, Dietz MA, Starmer CF, Palker TJ, Haynes BF.

J Immunol. 1989 Dec 1;143(11):3632-40.

PMID:
2479685
33.

Immunodominant sites of human T cell lymphotropic virus type 1 envelope protein for murine helper T cells.

Kurata A, Palker TJ, Streilein RD, Scearce RM, Haynes BF, Berzofsky JA.

J Immunol. 1989 Sep 15;143(6):2024-30.

PMID:
2528586
34.

Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.

Palker TJ, Matthews TJ, Langlois A, Tanner ME, Martin ME, Scearce RM, Kim JE, Berzofsky JA, Bolognesi DP, Haynes BF.

J Immunol. 1989 May 15;142(10):3612-9.

PMID:
2469721
35.
36.

Human T-cell lymphotropic virus I and adult T-cell leukemia: report of a cluster in North Carolina.

Weinberg JB, Spiegel RA, Blazey DL, Janssen RS, Kaplan JE, Robert-Guroff M, Popovic M, Matthews TJ, Haynes BF, Palker TJ.

Am J Med. 1988 Jul;85(1):51-8.

PMID:
2898891
37.

Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

Palker TJ, Clark ME, Langlois AJ, Matthews TJ, Weinhold KJ, Randall RR, Bolognesi DP, Haynes BF.

Proc Natl Acad Sci U S A. 1988 Mar;85(6):1932-6.

38.

Purification of envelope glycoproteins of human T cell lymphotropic virus type I (HTLV-I) by affinity chromatography.

Palker TJ, Clark ME, Sarngadharan MG, Matthews TJ.

J Virol Methods. 1987 Dec;18(4):243-55.

PMID:
2832431
39.

A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope.

Palker TJ, Matthews TJ, Clark ME, Cianciolo GJ, Randall RR, Langlois AJ, White GC, Safai B, Snyderman R, Bolognesi DP, et al.

Proc Natl Acad Sci U S A. 1987 Apr;84(8):2479-83.

40.
42.

Antibody against T lymphoblastic leukemia-associated antigen (3-40) identifies vimentin and keratin intermediate filaments in normal cells.

Laster AJ, Palker TJ, Harden EA, Ho W, Naito K, DuPont B, Haynes BF.

Blood. 1985 Sep;66(3):642-8.

PMID:
2411311
43.
45.

Human T-cell leukemia/lymphoma virus: studies of host-virus interaction.

Palker TJ, Bolognesi DP, Haynes BF.

Curr Top Microbiol Immunol. 1985;115:247-66. No abstract available.

PMID:
2579774
47.

Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, Palker TJ, Redfield R, Oleske J, Safai B, et al.

Science. 1984 May 4;224(4648):500-3.

PMID:
6200936
48.

Monoclonal antibodies against human T cell leukemia-lymphoma virus (HTLV) p24 internal core protein. Use as diagnostic probes and cellular localization of HTLV.

Palker TJ, Scearce RM, Miller SE, Popovic M, Bolognesi DP, Gallo RC, Haynes BF.

J Exp Med. 1984 Apr 1;159(4):1117-31.

49.

Differentiation of human T lymphocytes. I. Acquisition of a novel human cell surface protein (p80) during normal intrathymic T cell maturation.

Haynes BF, Harden EA, Telen MJ, Hemler ME, Strominger JL, Palker TJ, Scearce RM, Eisenbarth GS.

J Immunol. 1983 Sep;131(3):1195-200.

PMID:
6224850
50.

Identification of human T cell leukemia virus in a Japanese patient with adult T cell leukemia and cutaneous lymphomatous vasculitis.

Haynes BF, Miller SE, Palker TJ, Moore JO, Dunn PH, Bolognesi DP, Metzgar RS.

Proc Natl Acad Sci U S A. 1983 Apr;80(7):2054-8.

Supplemental Content

Loading ...
Support Center